Bulk Inquiry
ABT 869
- Linifanib
- Soluble in DMSO
- MF: C21H18FN5O
- MW: 375.4
Description
ABT 869 (Linifanib) is a multi-target receptor tyrosine kinase (RTK) inhibitor targeting VEGFRs, PDGFRs, FLT3 and c-KIT.
ABT 869 combines antiangiogenic VEGFR/PDGFR inhibition with activity against oncogenic kinases such as FLT3 and KIT. It is relevant for studying tumor vascularization, hematologic malignancy signaling and multi-kinase inhibitor mechanisms.
Key Features
- Multi-target RTK inhibitor
- Targets VEGFR, PDGFR, FLT3 and c-KIT kinases
- Blocks angiogenic and tumor-cell signaling pathways
- Useful for oncology kinase inhibitor profiling
Applications
- VEGFR/PDGFR kinase assays
- Angiogenesis model research
- FLT3-driven leukemia studies
- Multi-kinase inhibitor combination assays
More Information
| Parent CAS No. | 796967-16-3 |
|---|---|
| Chemical Name | 1-(4-(3-amino-1H-indazol-4-yl)phenyl)-3-(2-fluoro-5-methylphenyl)urea |
| SMILES | NC1=NNC2=CC=CC(C3C=CC(NC(=O)NC4C=C(C)C=CC=4F)=CC=3)=C12 |
| MFCD | MFCD11840918 |
| InChi | InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28) |
| InChiKey | MPVGZUGXCQEXTM-UHFFFAOYSA-N |
| CID | 11485656 |
| Short Description | RTK inhibitor |
References
- DH Albert et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 2006, 5, 995-1006.
- J Zhou et al. ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J. Hematol. Oncol. 2009, 2, 33.
- AK Ikeda et al. ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways. Mol. Cancer Ther. 2010, 9(3), 653-60.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1128 | Erlotinib hydrochloride |
From $77.00 |
| 1393 | Gefitinib |
From $77.00 |
| 1394 | Imatinib mesylate |
From $66.00 |
| 1395 | Lapatinib ditosylate |
From $88.00 |
| 1398 | Sunitinib malate |
From $88.00 |
| 1411 | Vandetanib |
From $55.00 |
| 1414 | AG 013736 |
From $55.00 |
| 1415 | CT 53518 |
From $77.00 |
| 1419 | AB 1010 |
From $77.00 |
| 1420 | Pazopanib hydrochloride |
From $66.00 |
| 1433 | CI 1033 |
From $66.00 |
| 1461 | Cediranib |
From $77.00 |
| 1506 | WZ 4002 |
From $77.00 |
| 1526 | Neratinib |
From $88.00 |
| 1544 | BIBW 2992 |
From $55.00 |
| 1547 | OSI 930 |
From $99.00 |
| 1581 | SU 11274 |
From $99.00 |
| 1582 | Foretinib |
From $99.00 |
| 1583 | PF 04217903 mesylate |
From $88.00 |
| 1632 | OSI 420 |
From $99.00 |
| 1637 | Vatalanib |
From $82.50 |
| 1653 | AEE 788 |
From $88.00 |
| 1660 | Crizotinib |
From $88.00 |
| 1662 | CP 547632 |
From $77.00 |
